Louise Chen
Stock Analyst at Scotiabank
(3.43)
# 964
Out of 5,114 analysts
300
Total ratings
47.02%
Success rate
4.35%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Initiates: Sector Outperform | $35 | $30.35 | +15.32% | 4 | Dec 5, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Sector Perform | $45 → $53 | $54.19 | -2.20% | 1 | Dec 4, 2025 | |
| MRK Merck & Co. | Maintains: Sector Outperform | $105 → $120 | $101.09 | +18.71% | 26 | Dec 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $767.96 | +0.27% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $21.04 | +280.23% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $3.14 | +186.62% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $25.55 | -45.21% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $2.88 | +317.39% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $19.99 | +175.14% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $78.57 | -30.00% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $2.75 | +445.45% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $99.73 | -49.86% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $5.68 | +164.08% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $39.55 | -57.02% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $72.34 | -3.23% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $19.85 | +151.89% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $10.49 | +185.99% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $18.04 | +204.88% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.32 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $48.09 | +232.71% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $46.42 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $226.82 | +5.81% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $25.19 | +78.64% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $206.37 | +4.18% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.31 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $22.41 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $1,071.44 | -17.40% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.07 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $26.68 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $19.48 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.60 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $220.80 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.73 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.52 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.80 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.89 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.63 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.23 | +1,912.38% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.27 | +120.26% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $13.55 | +269.00% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $28.01 | +78.51% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.70 | +194.12% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.59 | +1,435.57% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $1.17 | +144,230,669.23% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $288.54 | -10.58% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.30 | +3,746.15% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.31 | +1,426.72% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $7.87 | +471.79% | 1 | Jun 22, 2017 |
Teva Pharmaceutical Industries
Dec 5, 2025
Initiates: Sector Outperform
Price Target: $35
Current: $30.35
Upside: +15.32%
Bristol-Myers Squibb Company
Dec 4, 2025
Maintains: Sector Perform
Price Target: $45 → $53
Current: $54.19
Upside: -2.20%
Merck & Co.
Dec 4, 2025
Maintains: Sector Outperform
Price Target: $105 → $120
Current: $101.09
Upside: +18.71%
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $767.96
Upside: +0.27%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $21.04
Upside: +280.23%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $3.14
Upside: +186.62%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $25.55
Upside: -45.21%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $2.88
Upside: +317.39%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $19.99
Upside: +175.14%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $78.57
Upside: -30.00%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $2.75
Upside: +445.45%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $99.73
Upside: -49.86%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.68
Upside: +164.08%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $39.55
Upside: -57.02%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $72.34
Upside: -3.23%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $19.85
Upside: +151.89%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $10.49
Upside: +185.99%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $18.04
Upside: +204.88%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.32
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $48.09
Upside: +232.71%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $46.42
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $226.82
Upside: +5.81%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $25.19
Upside: +78.64%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $206.37
Upside: +4.18%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.31
Upside: -
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.41
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $1,071.44
Upside: -17.40%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.07
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $26.68
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.48
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.60
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $220.80
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.73
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.52
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.80
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.89
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.63
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.23
Upside: +1,912.38%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.27
Upside: +120.26%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $13.55
Upside: +269.00%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $28.01
Upside: +78.51%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.70
Upside: +194.12%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.59
Upside: +1,435.57%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $1.17
Upside: +144,230,669.23%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $288.54
Upside: -10.58%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.30
Upside: +3,746.15%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.31
Upside: +1,426.72%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $7.87
Upside: +471.79%